Cargando…

Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial

BACKGROUND: To increase the global supply of affordable IPV vaccine, preferably using Sabin viruses to comply with GAPIII requirements, Takeda has assessed three dosages of a stand-alone sIPV. METHODS: In this phase I/II study two cohorts of 40 adults and 60 toddlers, respectively, were initially as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cramer, Jakob P., Jimeno, José, Han, Htay Htay, Lin, Stella, Hartmann, Katharina, Borkowski, Astrid, Sáez-Llorens, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347011/ https://www.ncbi.nlm.nih.gov/pubmed/32563609 http://dx.doi.org/10.1016/j.vaccine.2020.05.081

Ejemplares similares

Immunogenicity and Safety of Inactivated Sabin-Strain Polio Vaccine “PoliovacSin”: Clinical Trials Phase I and II
por: Piniaeva, Anastasia, et al.
Publicado: (2021)

A novel gamma radiation-inactivated sabin-based polio vaccine
por: Tobin, Gregory J., et al.
Publicado: (2020)

In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine
por: Abd-Elghaffar, Asmaa A., et al.
Publicado: (2020)

Development of an animal component free production process for Sabin inactivated polio vaccine
por: Suarez-Zuluaga, Diego A., et al.
Publicado: (2022)

Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame
por: Gaensbauer, James T, et al.
Publicado: (2018)

Cost-effectiveness of various immunization schedules with inactivated Sabin strain polio vaccine in Hangzhou, China
por: Xu, Yuyang, et al.
Publicado: (2022)

Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine–only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants
por: Brickley, Elizabeth B, et al.
Publicado: (2018)

Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region
por: Tevi-Benissan, Carol, et al.
Publicado: (2017)

Albert Bruce Sabin: The Man Who Made the Oral Polio Vaccine
por: Orsini, Davide, et al.
Publicado: (2022)

Safety and Immunogenicity of a New Inactivated Polio Vaccine Made From Sabin Strains: A Randomized, Double-Blind, Active-Controlled, Phase 2/3 Seamless Study
por: Capeding, Maria Rosario, et al.
Publicado: (2020)

Experience With Inactivated Polio Vaccine Introduction and the “Switch” From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization’s Western Pacific Region
por: Gurung, Santosh, et al.
Publicado: (2017)

Resource Needs for the Trivalent Oral Polio to Bivalent Oral Polio Vaccine Switch in Indonesia
por: Holmes, Marionette, et al.
Publicado: (2017)

Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15–18 months
por: Sáez-Llorens, Xavier, et al.
Publicado: (2020)

Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine
por: Sáez-Llorens, Xavier, et al.
Publicado: (2022)

A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China
por: Lv, Huakun, et al.
Publicado: (2022)

Effect of HIV-exposure and timing of anti-retroviral treatment on immunogenicity of trivalent live-attenuated polio vaccine in infants
por: Moonsamy, Shelina, et al.
Publicado: (2019)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
por: Mo, Zhaojun, et al.
Publicado: (2017)

Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults
por: Spencer, Sarah, et al.
Publicado: (2021)

Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine
por: Shin, Woo-Jin, et al.
Publicado: (2018)

Regulatory Aspects of Sabin Type 2 Withdrawal From Trivalent Oral Poliovirus Vaccine: Process and Lessons Learned
por: Decina, Daniela, et al.
Publicado: (2017)

Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants
por: Gao, Shuyu, et al.
Publicado: (2022)

Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses
por: Wahid, Rahnuma, et al.
Publicado: (2021)

Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication
por: Kumar, Prashant, et al.
Publicado: (2022)

Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China
por: Tang, Xuewen, et al.
Publicado: (2023)

Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2018)

Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
por: Dietrich, Jes, et al.
Publicado: (2014)

Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer
por: Kotecha, Rishi S., et al.
Publicado: (2015)

Long-Term Immunogenicity of Inactivated and Oral Polio Vaccines: An Italian Retrospective Cohort Study
por: Larocca, Angela Maria Vittoria, et al.
Publicado: (2022)

Immunogenicity of Catch-Up Immunization with Conventional Inactivated Polio Vaccine among Japanese Adults
por: Fukushima, Shinji, et al.
Publicado: (2022)

Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine
por: Zhao, Ting, et al.
Publicado: (2021)

Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies
por: Resik, Sonia, et al.
Publicado: (2015)

Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial
por: Wang, Yamin, et al.
Publicado: (2021)

Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
por: Silveira, Fernando, et al.
Publicado: (2023)

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults
por: Beran, Jiří, et al.
Publicado: (2013)

The Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccination: A Study of Maternal-Cord Blood Pairs in Taiwan
por: Lin, Shin-Yu, et al.
Publicado: (2013)

Sabine's notebook : in which the extraordinary correspondence of Griffin & Sabine continues /
por: Bantock, Nick
Publicado: (1992)

Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
por: Ambrosino, Donna, et al.
Publicado: (2021)

Environmental Surveillance of Polioviruses in Armenia, Colombia before Trivalent Oral Polio Vaccine Cessation
por: González, María Mercedes, et al.
Publicado: (2019)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

Sabin polio virus protein 1 (VP1) evolution in patients with acute flaccid paralysis from 2010 to 2016 in Uganda
por: Nanteza, Mary Bridget, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r9d01nibqnrie1rtakmeoa2vpe